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Intermedin (IMD) or adrenomedullin 2 is a novel peptide related to the calcitonin gene-related peptide (CGRP) family. Via 
calcitonin receptor-like receptor/receptor activity modifying proteins, the common receptor complexes of CGRP, IMD exerts a 
wide range of biological effects, especially regulation of cardiovascular homeostasis. Proteolytic processing of a larger IMD 
precursor yields a series of biologically active C-terminal fragments, IMD1–53, IMD1–47 and IMD8–47. IMD and its recep-
tors are present in the cardiovascular system, and IMD is present at low levels in plasma. In the cardiovascular system, IMD 
has multiple functions such as regulation of blood pressure and cardiac function, pro-angiogenesis, endothelial barrier function 
protection, anti-oxidative stress, and anti-endoplasmic reticulum stress. IMD participates widely in the pathogenesis of athero-
sclerosis, hypertension, pulmonary arterial hypertension and vascular calcification. It is a vascular regulatory factor of homeo-
stasis and a vital endogenous protective factor against vascular diseases. 
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Intermedin (IMD) or adrenomedullin 2 (ADM2) is a novel 
biologically active polypeptide independently discovered in 
2004 [1,2]. Subsequently, the two peptides were found to 
have the same amino acid sequence and similar biological 
function, so they were considered the same substance. IMD 
is a novel member of the calcitonin/calcitonin gene-related 
peptide (CGRP) family, which includes calcitonin, CGRP, 
amylin, and ADM [1]. Their encoding genes are highly 
homologous and they play an important role in regulating 
the body homoeostasis and cardiovascular disease. IMD 
usually has similar biological effects as other members of 
the CGRP family, such as anti-oxidative stress effects, posi-
tive inotropic action, natriuretic and diuretic effects, regu-
lating hormone secretion, neurotransmission or neuromod-
ulation, and anti-apoptosis effects [310]. However, IMD 
actions differ from those of ADM. For instance, with a rat 
renal-impairment model prepared by 5/6 nephrectomy in 
Wistar Kyoto (WKY) rats, Hirose et al. [11] found IMD 
expression upregulated and that of ADM downregulated in 
the kidneys, so under certain pathological conditions, the 
pathophysiologic functions of IMD and ADM differ. The 
different biological functions for IMD and other members 
of the CGRP family may be related to the wider tissue dis-
tribution of IMD in the body, non-selectivity of IMD to 
CGRP family receptors and a possible specific IMD anti-
body. 
In recent years, growing evidence has indicated that IMD 
is a vital bioactive peptide maintaining vascular homeosta-
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sis and has extensive functions in the cardiovascular system, 
such as regulation of blood pressure and cardiac function, 
accelerating angiogenesis, and anti-apoptosis and powerful 
cardiovascular protective functions [9,1214]. IMD is 
widely involved in the pathogenesis of vascular disease 
such as hypertension, vascular calcification and atheroscle-
rosis [1517]. In this review, we summarize the effects of 
IMD on the cardiovascular system, the relationship between 
IMD and vascular diseases and the possible molecular 
mechanism maintaining vascular homeostasis. 
1  Biochemical characteristics of IMD 
1.1  Molecular structure of IMD 
Human IMD gene is located on the distal arm of chromo-
some 22 and encodes a prepro-peptide of 148 amino acids, 
called prepro-IMD. Basic proteolytic cleavage sites of pre-
pro-IMD are found at Arg100–Thr101 and Arg107–Val108; 
proteolytic cleavage at these sites followed by cleavage of 
Tyr147–Gly148 and amidation of the C-terminal amino acid 
yields a long 47 amino acid form of the peptide IMD147 
(prepro-IMD101–147) and a short 40 amino acid peptide  
IMD847 (prepro-IMD108–147) [1]. Subsequently, our 
laboratory identified another proteolytic cleavage site in rat 
prepro-IMD between Arg92–His93 and obtained an addi-
tional larger peptide IMD153 (prepro-IMD93–145), which 
may be the main active fragment of IMD [18] (Figure 1).  
IMD is highly conserved between different animal spe-
cies. The mouse and rat IMD147 molecules differ in one 
amino acid; the human IMD147 amino acid sequence is 
87% identical to that of rat and >60% identical to that of 
osteichthyes. The structure of IMD is more similar to ADM 
and CGRP than amylin (AMY) and calcitonin (CT), so IMD, 
ADM and CGRP are probably a sub-branch in the evolution 
of the CGRP superfamily [1]. IMD has a similar protein 
structure with members of the CGRP family, namely, an  
N-terminal intramolecular loop of six amino acids flanked 
by a disulphide bond, followed by an amidation structure of 
a C-terminal amide. These two special structures are im-
portant for the IMD biological effects. 
1.2  Distribution and production of IMD 
The main active fragments of IMD in plasma are IMD153, 
IMD147 and IMD847. The sensitivity of the body greatly 
affects plasma IMD levels [19]. The primary source of 
plasma IMD is not exactly known; pituitary secretion may 
be the main source [1]. 
Transcriptional expression and immunohistochemical 
investigation in rodents and humans revealed particularly 
high levels of IMD in the kidney, gastrointestinal tract (es-
pecially the muscularis mucosa of the stomach) [1] and je-
junum, brain (especially hypothalamus), skin, and submax-
illary gland. IMD levels are relatively high in the pancreas, 
lung, spleen, thymus and ovaries but low in the adrenal 
gland and testis [1,2]. In the mature mouse heart, pre-
pro-IMD is expressed at low levels, only in endothelial cells 
of the coronary artery and vein, and scarcely in myocardial 
cells [2]. The expression of IMD in healthy myocardial cells 
is low and is markedly upregulated under stress [20]. 
The relative paucity of IMD in the vicinity of the vascula-
ture indicates that IMD is primarily an endocrine peptide. 
The prominent distribution of IMD in the renal tubule sug-
gests a physiological role in local regulation of the wa-
ter-electrolyte balance and circulatory blood volume. Ro-
bust expression in the diseased myocardium as compared 
with sparse levels in the healthy myocardium supports an 
important role in pathogenesis of the heart. 
1.3  IMD receptors and signaling transduction pathway 
IMD belongs to the CGRP superfamily of peptides. The 
common receptors of the CGRP family are calcitonin re- 
 
 
Figure 1 (color online)  Schematic diagram of human prepro-intermedin, which generates different fragments derived from the proteolytic cleavage of 148 
amino-acid prepropeptide precursor at the putative cleavage sites indicated.  
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ceptor-like receptor/receptor activity modifying protein 
(CRLR/RAMP) complexes [1]. RAMPs act as molecular 
chaperones for trafficking CRLR from the endoplasmic 
reticulum and Golgi apparatus to the cell surface and have 
pivotal influence over the receptors’ pharmacological char-
acteristics. Given that RAMPs have three subtypes, there 
are three kinds of receptors. According to the affinity to 
CGRP and ADM, CRLR with RAMP1 offers the CGRP1 
receptor; with RAMP2 or RAMP3, it offers the ADM1 or 
ADM2 receptor. IMD binds non-selectively to all three 
CRLR/RAMP complexes [1]. As compared to CGRP, IMD 
is less potent at CGRP1 receptors but more potent at ADM1 
and ADM2 receptors; as compared with ADM, IMD is 
more potent at CGRP1 receptors but less potent at ADM1 
and ADM2 receptors. CRLR belongs to the G-protein-  
coupled receptor (GPCR) superfamily and has a complex 
downstream signaling pathway. Stimulating adenylate 
cyclase g protein Gs-mediated activation of adenylate 
cyclase-cyclic adenosine monophosphate-protein kinase A 
(AC-cAMP-PKA) represents the major signalling pathway 
coupled with these receptors [16,2124]. In addition, 
Gq/11-mediated coupling to phospholipase C-b, Gi and/or 
Go-mediated regulation of potassium channels, and activa-
tion of phosphatidylinositol 3-kinase-guanylate cyclase- 
cyclic guanosine monophosphate (PI3K-GC-cGMP) have 
been reported as downstream signaling pathways of IMD 
receptors [10,13,15,2527]. 
However, no specific receptor for IMD has been found. 
A large amount of evidence showed that IMD and ADM 
share many similar biological functions and IMD is stronger 
than ADM, but bonding to CRLR/RAMPs is not more po-
tent than for ADM. Antagonists of CGRP and ADM can 
block or abolish the biological effects of IMD in vivo. Like 
other members of the CGRP family, IMD exerts its biolog-
ical effect mainly through the common receptors CRLR/ 
RAMPs. CRLR belongs to the superfamily of sev-
en-transmembrane GPCRs [20]. It undergoes conformation-
al changes, which results in coupling to Gs, activation of 
AC and accumulation of intracellular cAMP when activated 
by IMD. cAMP accumulation can activate PKA. AC- 
cAMP-PKA forms the most important intracellular signal-
ing pathway of IMD. IMD is well known to increase the 
content of intracellular cAMP and mediate a variety of bio-
logical effects such as myocardial contraction, vasodilata-
tion, inhibition of vascular calcification, regulating cell pro-
liferation, hypertrophy, migration, and apoptosis [21,22,28]. 
The L-arginine-nitric oxide (NO)-cGMP signal pathway 
also plays an important role in the biological function of 
IMD. IMD treatment increased the activity of NO synthase 
(NOS) and content of NO in tissues and augmented the up-
take of L-arginine by cells [29]. NO activates GC and ele-
vates intracellular cGMP levels for multiple effects such as 
vasodilation, anti-oxidative stress, and inhibition of cell 
apoptosis [8,30,31]. IMD153 significantly increased NO 
production and endothelial NOS (eNOS) activity in rat aor-
tas and was more potent than equivalent ADM [32]. How-
ever, IMD and ADM had no effect on inducible NOS ex-
pression and activity. Otherwise, IMD153 dose-      
dependently increased [3H]L-Arg transport, and its effect 
was more potent than an equivalent concentration of ADM. 
Semiquantitative RT-PCR revealed that IMD153 signifi-
cantly increased the mRNA expression of cationic amino 
acid transport 1 (CAT-1) and CAT-2B. Thus, IMD153 
may regulate vessel function homeostasis by upregulating 
the L-arginine-NOS-NO pathway. The pulmonary vaso-
relaxant response (PVR) to recombinant IMD in pulmonary 
arterial (PA) rings were found completely inhibited by en-
dothelium removal and NO production inhibitors [27]. 
IMD-stimulated endothelial CRLR is coupled to release of 
NO, activation of GCs, and promotion of hyperpolarization 
through large-conductance calcium-activated K(+) channels 
in the rat main pulmonary artery. IMD had a negative ino-
tropic effect on the isolated myocardium because of 
NO-cGMP pathway activation with concomitant thin my-
ofilament desensitization by increased cTnI phosphorylation 
[25], which provides a coherent explanation for the previ-
ously reported contradictory results (positive or negative 
inotropic effect). In conscious rat models, the regional hae-
modynamic profile of IMD resembled that of ADM [30], 
and some of the vasodilator effects of IMD were mediated 
by ADM receptors and NO but not by K(ATP) channels. 
Using anaesthetic rat models, Abdelrahman et al. found that 
IMD dose-dependently decreased mean arterial pressure and 
increased heart rate; the depressive effect of IMD was not 
mediated via the L-arginine-NO pathway, production of 
prostanoids or opening of tetraethylammonium-sensitive K+ 
channels but was opposed by activity of the sympathetic 
nervous system [33]. IMD treatment attenuating hypoxic 
pulmonary vascular remodeling, activating the L-arginine- 
NO pathway and inhibiting the endoplasmic reticulum 
stress-specific apoptosis pathway could be the mechanisms 
mediating the anti-proliferative and anti-apoptotic effects of 
IMD [29] (Figure 2). 
2  IMD and vascular diseases 
A large amount of data showed that the changed expression 
of IMD and its receptor is involved in the initiation and de-
velopment process of various vascular diseases. IMD has a 
strong inhibitory effect on the development of these diseas-
es and may be a new target for prevention and treatment of 
such disease. 
2.1  IMD and atherosclerosis 
IMD has protective effect on the endothelial barrier function, 
so IMD could have a powerful anti-inflammatory effect. 
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IMD stabilized endothelial barriers in human umbilical vein 
endothelial cell (HUVEC) monolayers via CRLR/RAMP2 
receptors [23]. These effects were mediated via cAMP-  
mediated inactivation of contractility and strengthening of 
cell-cell adhesion. IMD increased the permeability of rat 
coronary microvascular endothelial cells (RCECs) and re-
duced that of HUVECs and rat aortic endothelial cells via 
CRLRs and cAMP [34]. IMD caused derangement of the  
actin cytoskeleton along with loss of vascular endothelial 
cadherin (VE-cadherin) in RCECs but caused rearrange-
ment of the actin cytoskeleton and VE-cadherin at cell-cell 
junctions in HUVECs. IMD inactivated the RhoA-Rho- 
kinase (Rock) pathway in both cell types. However, it inac-
tivated Rac1 in RCECs but not HUVECs. Inhibition and 
rescue experiments demonstrated that both RhoA and Rac1 
are required for RCEC barrier stability, whereas in HU-
VECs, the inhibition of RhoA/Rock signalling did not in-
terfere with basal permeability. Therefore, the opposite ef-
fects of IMD on permeability of RCECs and HUVECs are 
due to differential regulation of actin cytoskeleton dynamics 
via RhoA and Rac1. Moreover, Rac1 activity is regulated 
by the RhoA/Rock pathway in RCECs but not HUVECs. 
Human aortic endothelial cells were found to express IMD 
mRNA and secreted IMD peptide [8]. IMD mRNA expres-
sion depended on metabolic conditions and was selectively 
regulated in a contrary fashion to ADM mRNA. IMD 
mRNA expression in endothelial cells is markedly sensitive 
to oxidative stress, and IMD peptide itself has anti-apoptotic 
activity in human endothelial cells. These data suggest that 
the role of IMD differs from that of ADM and that IMD has 
a protective function in human endothelial cells. 
IMD has an inhibitory effect on the development of ath-
erosclerosis. Pretreatment with IMD for six weeks prevent-
ed the progression of atherosclerotic lesions and the in-
crease in wall thickness in the aorta [35]. Oil-red O staining 
of the entire aorta and the atherosclerotic aortic root section 
showed 2-fold decrease of atherogenic plaque. Serum lipid 
profiles such as total cholesterol and low-density lipoprotein 
(LDL) cholesterol levels were decreased and high-density 
lipoprotein cholesterol level was increased. Thus, exoge- 
 
 
Figure 2 (color online)  Schematic diagram outlining the signalling pathways by which IMD might evoke cardiovascular effects and be involved in protec-
tive effects on cardiovascular diseases. CRLR, calcitonin receptor-like receptor; RAMPs, receptor activity-modifying proteins; AC, adenylate cyclase; cAMP, 
cyclic adenosine monophosphate; PKA, protein kinase A; PKC, protein kinase C; GC, guanylate cyclase; cGMP, cyclic guanosine monophosphate; PKG, 
protein kinase G; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinase; Akt/PKB, protein 
kinase B; GSK-3β, glycogen synthase kinase-3 beta. 
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nous administration of IMD could prevent the progression 
of atherosclerotic plaque. The possible underlying mecha-
nisms may relate to the improvement of lipid profiles. Dai 
et al. [36] revealed a new mechanism of the anti-atherogenic 
role of IMD and a novel pattern for regulation of CD36 ex-  
pression in macrophages. In apolipoprotein E-deficient mice, 
six-week IMD infusion reduced oxidized LDL uptake, in-
tracellular cholesterol content, and foam-cell formation in 
peritoneal macrophages as well as the protein and mRNA 
levels of CD36. These in vivo results agreed with in vitro 
observations in primary peritoneal macrophages. Reduced 
CD36 protein and mRNA levels were due to IMD-     
accelerated decay of CD36 mRNA. Tristetraprolin (TTP), 
which binds to AU-rich elements in the 3′ untranslated re-
gions of mRNA and promotes its degradation, mediates 
CD36 mRNA destabilization. TTP knockdown by 
short-hairpin RNA increased and TTP overexpression re-
duced CD36 expression, and TTP knockdown rescued 
IMD-reduced CD36 expression. IMD attenuated macro-
phage foam-cell formation via TTP-mediated degradation of 
CD36 mRNA. In an in vitro foam-cell formation model 
(induced by acetylated LDL, Ac-LDL) with mouse 
(C57BL/6J) macrophages, IMD reduced Ac-LDL uptake 
and binding, decreased intracellular cholesterol content, and 
suppressed both mRNA and protein levels of scavenger 
receptor A (SR-A) [16]. Simultaneously, IMD increased 
phosphatase and tensin homolog (PTEN) protein levels by 
increasing PTEN phosphorylation and inhibiting ubiqui-
tin-mediated PTEN degradation. These effects were blocked 
by the IMD receptor antagonist or cAMP–PKA inhibitors. 
PTEN overexpression mimicked the inhibitory effects of 
IMD on SR-A expression and Ac-LDL uptake. However, 
knockdown of PTEN by short-hairpin RNA completely 
blocked all inhibitory effects of IMD. Furthermore, in 
apolipoprotein E-deficient mice, six-week IMD infusion 
reduced Ac-LDL uptake and SR-A mRNA and protein lev-
els and increased PTEN protein level in peritoneal macro-
phages. PTEN level was increased and SR-A expression 
decreased in parallel in macrophages in atherosclerotic le-
sions. Thus, IMD inhibited atherosclerosis in apoE mice. 
Increased stability of PTEN by IMD led to SR-A inhibition 
in macrophages, which ameliorated foam-cell formation and 
atherosclerosis in apoE mice. 
2.2  IMD and hypertension 
IMD also plays an important role in regulating vascular 
biology. Intraperitoneal injection of IMD1–47 had a hypo-
tensive effect on rat blood pressure. The hypotensive re-
sponse was markedly attenuated by treatment with 
CGRP8–37 in normotensive and spontaneously hyperten- 
sive rats (SHRs) [1]. Intravenous injection of IMD1–47 
decreased arterial pressure more potently than did ADM in 
mice [2]. IMD (0.330 nmol kg1) dose-dependently de-
creased mean arterial pressure and increased heart rate in 
anesthetized rats [33]. The depressive effect of IMD (3 
nmol kg1, ED70 dose) was not affected by pretreatment 
with an inhibitor of NOS, a cyclooxygenase inhibitor, or the 
nonspecific K+-channel blocker tetraethylammonium. Pre-
treatment with mecamylamine (ganglionic blocker) aug-
mented the depressive response and abolished the tachy-
cardic effect of IMD. Therefore, the depressive effect of 
IMD is not mediated via the L-arginine-NO pathway, the 
production of prostanoids or opening of tetraethylammo-
nium-sensitive K+ channels but is opposed by activity of the 
sympathetic nervous system. IMD, as a cardiovascular ac-
tive peptide, was found involved in reducing blood pressure 
and ameliorating cardiac function during hypertension [24]. 
The mechanism underlying this effect may involve its 
binding of a receptor complex formed by CRLR and 
RAMPs and consequent regulation of cAMP levels. Exonic 
insertion (I)/deletion (D) polymorphism was found to in-
fluence the generation of IMD-53, a DD carrier, as com-
pared with II and ID carriers, for a significantly higher 24-h 
artery blood pressure and lower estimated glomerular filtra-
tion rate [37]. The prevalence of chronic kidney disease as 
well as presence of lacunar infarction and white matter hy-
perintensity was greater for DD than II carriers (odds ratio 
2.4, P=0.01 and 2.7, P=0.003, respectively). The IMD I/D 
polymorphism was associated with renal dysfunction, blood 
pressure regulation and asymptomatic cerebrovascular dis-
eases in the Japanese general population. 
Site-specific microinjection of IMD bilaterally into the 
nucleus tractus solitarii (NTS) significantly increased renal 
sympathetic nerve activity (RSNA) and mean arterial pres-
sure (MAP) [22]. IMD-evoked increases in renal sympa-
thetic nerve activity and mean arterial pressure were abol-
ished by pretreatment with the receptor antagonist 
ADM2252, an AC inhibitor SQ22536 or a PKA inhibitor 
Rp-cAMP. However, pretreatment with another receptor 
antagonist CGRP837 did not suppress the increases in 
RSNA and MAP induced by IMD. Furthermore, IMD in-
creased the cAMP level, which was inhibited by 
ADM2252 pretreatment in the NTS. These results suggest 
that IMD participates in the sympathetic nerve activity and 
that central regulation of the cardiovascular system and a 
receptor-mediated cAMP-PKA signaling pathway is in-
volved in such IMD-induced effects in the NTS. 
Peripheral injection of IMD can relax blood vessels and 
decrease blood pressure by stimulating NO production [27]. 
Central treatment with IMD can activate the sympathetic 
nervous system and increase MAP [38]. In a rat renovascu-
lar hypertension model induced by 2-kidney 1-clip (2K1C) 
surgery, with bilateral paraventricular nucleus (PVN) mi-
croinjection of IMD, renal sympathetic nerve activity and 
MAP were decreased more in 2K1C than sham-operated 
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rats and were prevented by pretreatment with the ADM re-
ceptor antagonist ADM2252 or nonselective NOS inhibi-
tor NG-nitro-L-arginine methyl ester [39]. Microinjection of 
IMD into the PVN increased the NO metabolite (NOx) level 
in the PVN in 2K1C rats, which was prevented by 
ADM2252 treatment. Chronic PVN infusion of IMD re-
duced but ADM2252 increased blood pressure in con-
scious 2K1C rats. Therefore, IMD in the PVN inhibits 
sympathetic activity and attenuates hypertension in 2K1C 
rats, mediated by ADM1 and ADM2 receptors and its 
downstream NO. Therefore, the effect of IMD injection in 
the central nervous system on the sympathetic nervous sys-
tem and blood pressure still needs further study. 
As mentioned previously, the regulation of IMD on 
blood pressure is two-sided. Peripheral IMD can relax blood 
vessels and lower blood pressure, whereas central treatment 
with IMD usually activates the sympathetic nerve and ele-
vates blood pressure. Downregulation of IMD as an endog-
enous regulatory peptide may have a role in the progression 
of renal impairment and hypertension [11]. IMD mRNA 
levels were significantly lower in SHRs than WKY rats in 
all renal portions. In the remnant kidneys of 5/6 nephrecto-
mized rats, IMD mRNA levels were significantly decreased 
on days 3 and 56, whereas mRNA levels of CRLR, RAMP1, 
and RAMP2 were increased. Elevated IMD level and its 
receptor in the cardiovascular tissue may play an important 
role in the pathogenesis of spontaneous hypertension [17]. 
Immunoreactive IMD concentration was enhanced in the 
SHR myocardium, aortas and plasma, and IMD affected 
cAMP generation in the myocardium and aorta. In hyper-
tensive DOCA-salt rats, IMD administration significantly 
lowered blood pressure, increased urine volume, and re-
stored creatinine clearance [40]. IMD also greatly decreased 
superoxide formation and media thickness in the aorta. IMD 
gene delivery reduced vascular injury. Moreover, IMD gene 
transfer markedly decreased myofibroblast and collagen 
accumulation associated with decreased transforming 
growth factor-1 levels.  
2.3  IMD and vascular calcification 
Vascular calcification (VC) is highly associated with in-
creased morbidity and mortality in patients with advanced 
chronic kidney disease [41]. Paracrine/autocrine factors 
such as vasoactive peptides are involved in VC develop-
ment. Our laboratory [15] reported that IMD may be an 
endogenous vasoprotective factor for VC. Rat VC was in-
duced by administration of vitamin D3 plus nicotine (VDN). 
VDN-treated rat aortas showed lower IMD content and in-
creased expression of its receptors, along with increased 
vascular calcium deposition and alkaline phosphatase (ALP) 
activity. Low IMD levels were accompanied by increased 
calcium deposition in human atherosclerotic plaques. IMD 
greatly reduced vascular calcium deposition and ALP activ-
ity in VDN-treated rats. Concurrently, the loss of smooth- 
muscle lineage markers and matrix gamma-carboxyglu- 
tamic acid (Gla) protein (cMGP) in aortas was ameliorated 
by IMD in rats with VC, and the increased levels of phos-
pho-Smad (1/5/8) and core binding factor -1 in calcified 
vasculature were also reduced. However, the inhibitory ef-
fects of IMD on VC were eliminated on pre-treatment with 
warfarin or small interfering RNA to reduce cMGP level. 
Therefore, reduced endogenous IMD levels are associated 
with increased mineralization in vivo, and administration of 
IMD inhibited VC development by increasing cMGP level. 
IMD153 attenuated vascular smooth muscle cell (VSMC) 
calcification by inhibiting endoplasmic reticulum stress 
(ERS) through cAMP/PKA signaling [28]. IMD153 treat-
ment significantly alleviated the protein expression of ERS 
hallmarks activating transcription factor 4 (ATF4), ATF6, 
glucose-regulated protein 78 (GRP78) and GRP94. ERS 
occurred in early and late calcification of VSMCs but was 
inhibited by IMD153. These inhibitory effects of 
IMD153 were abolished by treatment with the PKA inhib-
itor H89. Pretreatment with IMD153 decreased the number 
of apoptotic VSMCs and downregulated the protein expres-
sion of cleaved caspase 12 and C/EBP homologous protein 
(CHOP) in calcified VSMCs. Concurrently, IMD153 re-
stored the loss of VSMC lineage markers and ameliorated 
calcium deposition and ALP activity in calcified VSMCs.  
2.4  IMD and pulmonary arterial hypertension 
Recently, lots of data showed that IMD is involved in pul-
monary arterial hypertension (PAH) pathogenesis. In PAH 
rats induced by hypoxia, mRNA levels and protein expres-
sions of IMD, CRLR and RAMPs had changed apparently 
in right ventricle (RV), lung tissue and blood plasma 
[4244]. In hypoxia rats, the concentration and mRNA level 
of IMD in plasma increased [42,44]. However, in lung tis-
sue of hypoxia rats, IMD contents decreased but mRNA 
level of IMD was up-regulated; meanwhile, the mRNA lev-
els of RAMP1 and CRLR were down-regulated [43,44]. In 
right ventricular tissue of hypoxia rats, IMD contents and 
mRNA levels of IMD and RAMP2 were higher [42]. Yang 
[45] discovered that in patients with chronic cor pulmonale 
at high altitude area, the levels of plasma IMD and mean 
pulmonary arterial pressure (mPAP) were markedly higher 
compared with those of healthy people.  
Pang et al. [46] demonstrated that IMD alleviated the 
development of pulmonary hypertension and pulmonary 
vascular structural remodeling induced by high pulmonary 
blood flow through NOS/NO pathway. In high pulmonary 
blood flow rats by abdominal aorta and inferior vena cava 
shunting, mPAP, the ratio of right ventricular mass to left 
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ventricular plus septal mass RV/(LV+SP), the musculariza-
tion of small pulmonary vessels and relative medial thick-
ness of pulmonary artery were all significantly increased. 
Meanwhile, the content of NO in the serum and pulmonary 
tissue homogenate and the expression of eNOS protein in 
rats of shunt group was all significantly decreased. IMD 
significantly decreased the mPAP and RV/(LV+SP), allevi-
ated the changes of pulmonary vascular micro-structure, 
with the elevation of the content of NO in the serum and 
pulmonary tissue homogenate and the expression of pul-
monary eNOS protein in shunting rats. Mao et al. [29] re-
ported that IMD treatment alleviated PAH and prevented 
RV hypertrophy. IMD inhibited hypoxic pulmonary vascu-
lar remodeling as indicated by reduced wall thickness and 
increased lumen diameter of pulmonary arterioles, and de-
creased muscularization of distal pulmonary vasculature in 
hypoxia-exposed rats. IMD treatment inhibited pulmonary 
artery smooth muscle cell (PASMC) proliferation and pro-
moted PASMC apoptosis. IMD treatment increased tissue 
level of constitutive NO synthase activity and tissue NO 
content in lungs, and enhanced L-arginine uptake into pul-
monary vascular tissues. IMD treatment increased cellular 
levels of glucose-regulated protein (GRP) 78 and GRP94, 
two major markers of endoplasmic reticulum (ER) stress, 
and increased caspase-12 expression, the ER stress-specific 
caspase, in lungs and cultured PASMCs. These results 
demonstrated that IMD treatment attenuates hypoxic pul-
monary vascular remodeling, and thereby hypoxic PAH 
mainly by inhibiting PASMC proliferation. Promotion of 
PASMC apoptosis may also contribute to the inhibitory 
effect of IMD. Activations of L-arginine-NO pathway and 
of ER stress-specific apoptosis pathway could be the mech-
anisms mediating the anti-proliferative and pro-apoptotic 
effects of IMD. 
3  Conclusion and future perspectives 
Growing evidence indicates that IMD is a vital regulatory 
factor of cardiovascular homoeostasis and is involved in the 
occurrence and development of various vascular diseases. 
IMD has a protective effect on atherosclerosis, vascular 
calcification, and hypertension and could be a novel target 
for treatment of cardiovascular system diseases. IMD exerts 
its functions through the common receptor of the CGRP 
superfamily of receptors, CRLR/RAMPs, and is non-   
selective to three kinds of CRLR/RAMPs. Therefore, inves-
tigators are interested in whether specific receptors of IMD 
exist in humans, which element in humans may influence 
the attraction of IMD and ADM to CRLR/RAMPs and how 
the change in attraction is regulated. IMD signal transduc-
tion pathways are complicated. Moreover, IMD147, 
IMD847, IMD153, and the different active segments of 
IMD, have independent roles and also show synergistic or 
antagonistic interaction in regulating gene expression, bio-
logical effect, receptor binding, receptor signal transduction, 
genesis and development of disease (the theory of intramo-
lecular regulation). The production of IMD animals, small 
interfering RNA, and specific inhibitor of IMD may play a 
vital role in research into the biological function of endog-
enous IMD and the molecular mechanisms involved. Con-
firmation of a crucial beneficial role of IMD should pave 
the way for translational research to the clinical arena. First, 
the potential of measuring IMD as a cardiovascular diseases 
biomarker could be addressed. Second, strategies could be 
devised to deliver IMD in the acute or chronic setting, such 
as infusion of the recombinant peptide or adenoviral vec-
tor-mediated delivery of the IMD gene to prevent or lessen 
the extent of vascular diseases. 
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